CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13
Jean C. Tien(University of Michigan), Arul M. Chinnaiyan(University of Michigan), Jianzhang Yang(Jinan University), Rachel Brough(Institute of Cancer Research), Jonathan Chou(UCSF Helen Diller Family Comprehensive Cancer Center), Felix Y. Feng(University of Michigan), Somnath Mahapatra(University of Michigan), Sanjana Eyunni(University of Michigan), Xuhong Cao(Howard Hughes Medical Institute), James Neiswender(Institute of Cancer Research), Ryan J. Rebernick(University of Michigan), Abhijit Parolia(University of Michigan), Marcin Cieślik(University of Michigan), Rahul Mannan(University of Michigan), Estefanía Labanca(The University of Texas MD Anderson Cancer Center), Stephanie J. Miner(University of Michigan), Dan R. Robinson(University of Michigan), Stephen J. Pettitt(Gene Therapy Laboratory), Christopher J. Lord(Institute of Cancer Research), Yi‐Mi Wu, Xiaoming Wang(Wannan Medical College), Zhen Wang(Jinan University), Yuping Zhang(First Affiliated Hospital of Jiangxi Medical College), Yu Chang(University of Michigan), Yuzhuo Wang(BC Cancer Agency), Xiaoju Wang(Shanxi Agricultural University), Yunhui Cheng(University of Michigan), Caleb Cheng(University of Michigan), Lanbo Xiao(University of Michigan), Palak Shah(University of Michigan), Abigail J. Todd(University of Michigan), Jie Luo(University of South China), Ke Ding(China Pharmaceutical University), Yi Bao(University of Michigan), Licheng Zhou(Jinan University)
Cited by 28
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k